COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression (stock up 7% and moving quick). ShroomBoom?
https://compasspathways.com/psilocybin-therapy-216-patients/
